Volume 21, Issue 3 pp. 343-350
Original Article

Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A

S. Kepa

S. Kepa

Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

Search for more papers by this author
B. Horvath

B. Horvath

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

Search for more papers by this author
S. Reitter-Pfoertner

S. Reitter-Pfoertner

Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

Search for more papers by this author
M. Schemper

M. Schemper

Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria

Search for more papers by this author
P. Quehenberger

P. Quehenberger

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

Search for more papers by this author
M. Grundbichler

M. Grundbichler

Division of Haematology and Oncology, Department of Internal Medicine III, Medical University of Salzburg, Salzburg, Austria

Search for more papers by this author
M. Heistinger

M. Heistinger

Department of Internal Medicine I, Clinical Centre of Klagenfurt am Woerthersee, Klagenfurt am Woerthersee, Austria

Search for more papers by this author
P. Neumeister

P. Neumeister

Division of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

Search for more papers by this author
C. Mannhalter

C. Mannhalter

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

Search for more papers by this author
I. Pabinger

Corresponding Author

I. Pabinger

Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

Correspondence: Ingrid Pabinger, Medical University of Vienna, Department of Medicine I, Clinical Division of Haematology and Haemostaseology, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

Tel.: +43 1 40400 44480; fax: +43 1 4040027430;

e-mail: [email protected]

Search for more papers by this author
First published: 13 January 2015
Citations: 58

Summary

In haemophilia A patients factor VIII (FVIII) recovery and half-life can vary substantially. There are parameters known to modulate FVIII pharmacokinetics (PK), but they explain only about 34% of the variability. The aim of this study was to identify new parameters that influence FVIII PK and thus to expand the current knowledge. FVIII PK were determined in 42 haemophilia A patients (37 severe, 5 moderate) without inhibitor. Patients' characteristics and laboratory parameters were evaluated for an association with FVIII PK. We analysed plasma levels of low-density lipoprotein receptor-related protein 1 (LRP1) and protein C (PC) activity, which had been hypothesized to influence FVIII activity. Furthermore, four variations in intron 6 of the LRP1 gene, which had been shown to influence LRP1, were investigated. FVIII half-life differed widely from 6.2 to 20.7 h, with a median of 10.0 h. Patients with blood group O had shorter FVIII half-life compared to patients with non-O blood group (median FVIII half-life 9.0 h vs. 10.4 h, P = 0.018). Age was significantly associated with FVIII half-life (r = 0.32, P = 0.035). Besides age, also VWF antigen (r = 0.52, P < 0.001) and blood group (r = −0.37, P = 0.015) was associated with FVIII half-life. No correlation was found with FVIII- or LRP1-genotype, LRP1 or PC concentrations. Our data showed large differences in FVIII PK between individual patients and revealed age, blood group and VWF levels as important determining factors for FVIII half-life. FVIII genotype or levels of LRP1 or PC had no influence on FVIII PK.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.